Bayer Finds U.S. Not A Fertile Market For Pre-Menopausal Women’s Health
This article was originally published in Pharmaceutical Approvals Monthly
Bayer, one of the world’s largest women’s health firms, is looking East and South for growth in its women’s health franchise, shifting its attention away from mature markets in the U.S. and Europe.
You may also be interested in...
Acquisition is based on the prospects for Immunomedics’ Trodelvy, but regulatory changes, manufacturing challenges, and research dynamics could upset even the best-laid plans.
Keeping Track: Terlipressin Falls Short Of US FDA Approval; Novel NDAs From Pfizer And Apellis; New BTDs For Sanofi, BeyondSpring
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Round-up of late summer applications recently submitted to US FDA, adapted from the Pink Sheet FDA Performance Tracker's User Fee Goal Dates chart.